Literature DB >> 22914051

Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.

Lacey Gunn1, Chuanlin Ding, Min Liu, Yunfeng Ma, Chunjian Qi, Yihua Cai, Xiaoling Hu, Deep Aggarwal, Huang-Ge Zhang, Jun Yan.   

Abstract

Promoting complement (C) activation may enhance immunological mechanisms of anti-tumor Abs for tumor destruction. However, C activation components, such as C5a, trigger inflammation, which can promote tumor growth. We addressed the role of C5a on tumor growth by transfecting both human carcinoma and murine lymphoma with mouse C5a. In vitro growth kinetics of C5a, control vector, or parental cells revealed no significant differences. Tumor-bearing mice with C5a-transfected xenografted tumor cells had significantly less tumor burden as compared with control vector tumors. NK cells and macrophages infiltrated C5a-expressing tumors with significantly greater frequency, whereas vascular endothelial growth factor, arginase, and TNF-α production were significantly less. Tumor-bearing mice with high C5a-producing syngeneic lymphoma cells had significantly accelerated tumor progression with more Gr-1+CD11b+ myeloid cells in the spleen and overall decreased CD4+ and CD8+ T cells in the tumor, tumor-draining lymph nodes, and the spleen. In contrast, tumor-bearing mice with low C5a-producing lymphoma cells had a significantly reduced tumor burden with increased IFN-γ-producing CD4+ and CD8+ T cells in the spleen and tumor-draining lymph nodes. These studies suggest concentration of local C5a within the tumor microenvironment is critical in determining its role in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22914051      PMCID: PMC3436956          DOI: 10.4049/jimmunol.1200846

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

Review 1.  Can NK cells be a therapeutic target in human cancer?

Authors:  Christopher J Chan; Daniel M Andrews; Mark J Smyth
Journal:  Eur J Immunol       Date:  2008-11       Impact factor: 5.532

2.  Generation of C5a in the absence of C3: a new complement activation pathway.

Authors:  Markus Huber-Lang; J Vidya Sarma; Firas S Zetoune; Daniel Rittirsch; Thomas A Neff; Stephanie R McGuire; John D Lambris; Roscoe L Warner; Michael A Flierl; Laszlo M Hoesel; Florian Gebhard; John G Younger; Scott M Drouin; Rick A Wetsel; Peter A Ward
Journal:  Nat Med       Date:  2006-05-21       Impact factor: 53.440

3.  Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.

Authors:  Peter N Lalli; Michael G Strainic; Min Yang; Feng Lin; M Edward Medof; Peter S Heeger
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

4.  Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production.

Authors:  Chongyun Fang; Xinhua Zhang; Takashi Miwa; Wen-Chao Song
Journal:  Blood       Date:  2009-06-02       Impact factor: 22.113

5.  Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice.

Authors:  Chongyun Fang; Takashi Miwa; Hao Shen; Wen-Chao Song
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 6.  NKG2D ligands in tumor immunity.

Authors:  N Nausch; A Cerwenka
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

7.  Cancer and complement.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Nat Biotechnol       Date:  2008-12       Impact factor: 54.908

8.  Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells.

Authors:  Michael G Strainic; Jinbo Liu; Danping Huang; Fengqi An; Peter N Lalli; Nasima Muqim; Virginia S Shapiro; George R Dubyak; Peter S Heeger; M Edward Medof
Journal:  Immunity       Date:  2008-03-06       Impact factor: 31.745

Review 9.  The role of membrane complement regulatory proteins in cancer immunotherapy.

Authors:  Jun Yan; Daniel J Allendorf; Bing Li; Ruowan Yan; Richard Hansen; Rossen Donev
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

10.  Modulation of the antitumor immune response by complement.

Authors:  Maciej M Markiewski; Robert A DeAngelis; Fabian Benencia; Salome K Ricklin-Lichtsteiner; Anna Koutoulaki; Craig Gerard; George Coukos; John D Lambris
Journal:  Nat Immunol       Date:  2008-09-28       Impact factor: 25.606

View more
  40 in total

1.  Mutation Drivers of Immunological Responses to Cancer.

Authors:  Eduard Porta-Pardo; Adam Godzik
Journal:  Cancer Immunol Res       Date:  2016-07-11       Impact factor: 11.151

Review 2.  Complement in monoclonal antibody therapy of cancer.

Authors:  Laura M Rogers; Suresh Veeramani; George J Weiner
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 3.  Novel mechanisms and functions of complement.

Authors:  George Hajishengallis; Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Immunol       Date:  2017-11-16       Impact factor: 25.606

Review 4.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

Review 5.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

6.  Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Authors:  Daniel Ajona; Carolina Zandueta; Leticia Corrales; Haritz Moreno; María J Pajares; Sergio Ortiz-Espinosa; Elena Martínez-Terroba; Naiara Perurena; Fernando J de Miguel; Eloisa Jantus-Lewintre; Carlos Camps; Silvestre Vicent; Jackeline Agorreta; Luis M Montuenga; Ruben Pio; Fernando Lecanda
Journal:  Am J Respir Crit Care Med       Date:  2018-05-01       Impact factor: 21.405

7.  Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.

Authors:  P Macor; E Secco; N Mezzaroba; S Zorzet; P Durigutto; T Gaiotto; L De Maso; S Biffi; C Garrovo; S Capolla; C Tripodo; V Gattei; R Marzari; F Tedesco; D Sblattero
Journal:  Leukemia       Date:  2014-06-06       Impact factor: 11.528

Review 8.  Immunological effects and therapeutic role of C5a in cancer.

Authors:  Victoria R Darling; Ralph J Hauke; Stefano Tarantolo; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-12       Impact factor: 4.473

9.  Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.

Authors:  Stephanie Downs-Canner; Deepa Magge; Roshni Ravindranathan; Mark E O'Malley; Lily Francis; Zuqiang Liu; Z Sheng Guo; Natasa Obermajer; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2015-08-20       Impact factor: 5.344

10.  Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.

Authors:  Ruey-Shyang Soong; Liwen Song; Janson Trieu; Jayne Knoff; Liangmei He; Ya-Chea Tsai; Warner Huh; Yung-Nien Chang; Wen-Fang Cheng; Richard B S Roden; T-C Wu; Cornelia L Trimble; Chien-Fu Hung
Journal:  Clin Cancer Res       Date:  2014-06-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.